Cypherpunk Technologies Inc. (CYPH) is a Cambridge, Massachusetts-based privacy technology company that reinvented itself from a clinical-stage biotech, Leap Therapeutics, into a Zcash-focused digital asset treasury and mining operation backed by Cameron and Tyler Winklevoss. Its shares climbed 10.88% to $2.14 on Tuesday morning, compared with the prior session's close of $1.925, a gain of $0.21. The move was a straightforward sympathy trade: Zcash, the asset that dominates Cypherpunk's balance sheet, rallied roughly 10% to about $950 after a sharp multi-week selloff, and the equity followed the token higher. No company-specific disclosure was issued Tuesday.
Cypherpunk's stock has effectively become a leveraged expression of Zcash sentiment, and Tuesday's session showed that relationship clearly. ZEC fell for eight consecutive sessions from November 7 to November 14, touching an intraday low near $801 and losing more than 25% of its value in a week. On Tuesday the token reversed, climbing more than 10% to trade near $950, and Cypherpunk's shares moved nearly in tandem.
Two forces drove the token bounce. First, a community vote opened on restructuring Zcash's development fund, proposing to redirect 8% of new issuance from Zcash Community Grants to a new development and legal defense fund. If approved, the plan would require 50,000 ZEC to be pulled from circulation within 30 days and routed through the Network Sustainability Mechanism. The vote is advisory and non-binding, but it framed the change as a temporary supply reduction. Second, the rebound was technical: after eight down days, liquidation data showed short positions accounting for the overwhelming majority of forced closes in the final twelve hours of the move, consistent with a short squeeze layered on oversold conditions.
The rally also extended a modest positive reaction to Monday's third-quarter report, which was released before the opening bell. Cypherpunk posted its first quarter of operating profit — $2.6 million — after its Zcash mining fleet mined 8,967.29 ZEC across 44 days, generating $9.9 million in revenue at roughly $104 in hosting cost per token and about 95% uptime. Headline net income of $306.0 million was almost entirely non-cash, reflecting a $330.8 million unrealized gain as ZEC rose from $400.09 at the end of June to $1,414.56 at the end of September.
The company reported 341,858.75 ZEC held, or about 2.01% of circulating supply, against a long-term target of at least 5%. It also resumed open-market purchases during the token's pullback, buying 3,775.72 ZEC at an average of $920.40, and signed a letter of intent with Bitmain for up to $30 million of next-generation mining machines expected in mid-2027. Shares rose just 2.94% on Monday, so the earnings release supported Tuesday's advance rather than triggering it.
Participation has been heavy but has cooled from autumn extremes. Daily turnover over the past month has generally run between 8 million and 14 million shares, including 12.2 million on Monday, below the 15 million to 22 million share sessions seen when the stock peaked in late September. Tuesday's early volume added to that elevated base.
The move diverged from the broad tape: major equity indices and Bitcoin were little changed, so this was not a market-wide risk-on day, though crypto-linked equities generally firmed with the token complex. Technically, the advance lifted Cypherpunk off the $1.67 low set Monday, yet the shares remain well below their 20-day average of roughly $2.64 and about 49% below the 52-week high of $4.19 reached in September. The stock is still working off a decline from above $4 that began in early October.
The score runs on a 0-to-100 scale, where 0 means no meaningful news and a move that is ordinary for the stock, and 100 means transformative news paired with an extreme, rare price move. Cypherpunk earns 28 out of 100.
The verified catalyst was moderate: an advisory governance vote affecting the underlying token and a solid quarterly report that produced a first operating profit, but no company-specific announcement on the day of the move. The price reaction was unremarkable by this stock's standards — a 10.88% gain against a typical daily absolute move of roughly 9.1% over the last 60 sessions, or about 1.2 times normal, with 22 of those sessions producing equal or larger swings. Both components are weak, which keeps the score in the low range.
With the third quarter reported, attention shifts to the company's ability to convert mining economics into recurring results. Investors will look for a full quarter of production, confirmation that uptime holds near 95% as the fleet expands, and progress toward the stated 5% supply and 25% hashrate targets ahead of the mid-2027 Bitmain delivery. Zcash's network hashrate growth bears watching, since Cypherpunk's share of it has already slipped from about 18% at launch to roughly 13%.
The dominant variable remains the ZEC price. At $950, the treasury is worth roughly $325 million on paper, and the direction of that mark drives reported earnings through the embedded derivative. Persistent ETF outflows from privacy-focused funds, regulatory scrutiny of privacy coins, continued at-the-market share issuance, and the non-binding nature of the community vote are the key risks, alongside the possibility that the token's bounce fades below $900.
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, so investors can compare approaches and match them to their own objectives. Reviewing the Trending AI Robots list is a practical next step for anyone exploring systematic strategies in volatile names.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CYPH moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend. In 45 of 50 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYPH as a result. In 64 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for CYPH turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 32 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
The 10-day moving average for CYPH crossed bearishly below the 50-day moving average on November 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CYPH entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +21.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where CYPH advanced for three days, in 216 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. CYPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.228) is normal, around the industry mean (2.423). P/E Ratio (4.500) is within average values for comparable stocks, (8.341). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.318). Dividend Yield (0.000) settles around the average of (0.274) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (15.906).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in clinical stage immuno-oncology
Industry InvestmentManagers